[go: up one dir, main page]

DK0650485T3 - 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser - Google Patents

2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser

Info

Publication number
DK0650485T3
DK0650485T3 DK93918182T DK93918182T DK0650485T3 DK 0650485 T3 DK0650485 T3 DK 0650485T3 DK 93918182 T DK93918182 T DK 93918182T DK 93918182 T DK93918182 T DK 93918182T DK 0650485 T3 DK0650485 T3 DK 0650485T3
Authority
DK
Denmark
Prior art keywords
diaryl
inflammatory
lipoxygenase
paf
acting
Prior art date
Application number
DK93918182T
Other languages
English (en)
Inventor
Xiong Cai
San-Bao Hwang
David Killian
T Y Shen
Sajjat Hussoin
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/912,788 external-priority patent/US5358938A/en
Priority claimed from US07/933,991 external-priority patent/US5434151A/en
Priority claimed from US08/062,391 external-priority patent/US5648486A/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK0650485T3 publication Critical patent/DK0650485T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93918182T 1992-07-13 1993-07-13 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser DK0650485T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/912,788 US5358938A (en) 1992-07-13 1992-07-13 Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US07/933,991 US5434151A (en) 1992-08-24 1992-08-24 Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US08/062,391 US5648486A (en) 1992-07-13 1993-05-12 Compounds and methods for the treatment of inflammatory and immune disorders
PCT/US1993/006575 WO1994001430A1 (en) 1992-07-13 1993-07-13 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
DK0650485T3 true DK0650485T3 (da) 2001-01-22

Family

ID=27129612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918182T DK0650485T3 (da) 1992-07-13 1993-07-13 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser

Country Status (13)

Country Link
US (2) US6294574B1 (da)
EP (1) EP0650485B1 (da)
JP (1) JPH08502243A (da)
AT (1) ATE196903T1 (da)
AU (1) AU666578B2 (da)
CA (1) CA2140034A1 (da)
DE (1) DE69329550T2 (da)
DK (1) DK0650485T3 (da)
ES (1) ES2152952T3 (da)
GR (1) GR3035063T3 (da)
HU (1) HUT72601A (da)
PT (1) PT650485E (da)
WO (1) WO1994001430A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639782A (en) * 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
JPH08502243A (ja) 1992-07-13 1996-03-12 サイトメッド，インコーポレイテッド 炎症性および免疫性疾患の治療のための２，５‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
BR9508196A (pt) * 1994-06-27 1997-09-02 Cytomed Inc Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
AU750592B2 (en) 1998-07-03 2002-07-25 Millennium Pharmaceuticals, Inc. Methods for synthesis of substituted tetrahydrofuran compound
CA2345919A1 (en) 1998-07-03 2000-01-13 Gangavaram Vasantha Madhava Sharma Substituted oxygen alicyclic compounds, including methods for synthesis thereof
AU4856199A (en) * 1998-07-03 2000-01-24 Millennium Pharmaceuticals, Inc. Substituted nitrogen and sulfur alicyclic compounds, including methods for synthesis thereof
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2690988A (en) 1952-12-24 1954-10-05 Stauffer Chemical Co Insecticidal substituted 1, 3-dithiolanes and method of application
US3852601A (en) 1971-07-15 1974-12-03 Ital Elettionica Spa Scanning device for scintigraphy according to three orthogonal planes
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4656190A (en) 1983-11-14 1987-04-07 Merck & Co., Inc. Indene derivatives and their use as PAF-antagonists
US4539332A (en) * 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US4595693A (en) 1984-06-04 1986-06-17 Merck & Co., Inc. Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US4871756A (en) 1985-03-20 1989-10-03 Merck Frosst Canada, Inc. Leukotriene antagonists
US4604407A (en) 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
NZ215866A (en) * 1985-04-22 1989-11-28 Merck & Co Inc 2,5-di(aryl/heterocyclyl) tetrahydro-furans and pharmaceutical compositions
US4876346A (en) 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4891363A (en) 1985-07-26 1990-01-02 Sankyo Company Limited Cyclic ether derivatives and their use
DE3701344A1 (de) 1986-01-21 1987-07-23 Boehringer Ingelheim Kg Neue thieno-1,4-diazepine
FR2601016B1 (fr) 1986-07-04 1988-10-07 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
US4910206A (en) 1986-07-14 1990-03-20 Sandoz Pharmaceuticals Corp. 5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists
DE3724031A1 (de) 1986-07-22 1988-01-28 Boehringer Ingelheim Kg Neue hetrazepine und verfahren zu ihrer herstellung
DE3724164A1 (de) 1986-07-25 1988-01-28 Boehringer Ingelheim Kg Neue 1,4-benzodiazepine, ihre herstellung und verwendung
DE3778248D1 (de) 1986-08-21 1992-05-21 Merck & Co Inc 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
US4841968A (en) 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
GB2197650A (en) * 1986-11-21 1988-05-25 Merck & Co Inc Process for preparing 2,5-diphenyl tetrahydrofurans and analogs thereof
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
US4916145A (en) 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
GB2209031A (en) 1987-08-24 1989-04-26 Merck & Co Inc Processes for preparing 1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists
CA1334975C (en) 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
JPH01149764A (ja) 1987-12-07 1989-06-12 Green Cross Corp:The ビス−ｓ−アルキルベンゼン誘導体
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
NZ227287A (en) * 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
US4845129A (en) 1988-03-14 1989-07-04 Sandoz Pharm. Corp. Diaryl substituted cyclopentane and cyclopentene derivatives
EP0338993A1 (en) 1988-04-21 1989-10-25 Sandoz Ag 6-Aryl-substituted-4h-thieno[2,3-e][1,2,4]triazolo [3,4-c][1,4]diazepines
US4992428A (en) 1988-05-05 1991-02-12 Sandoz Pharm. Corp. 5-aryl-substituted-2,3-dihydro-imidazo[1,2-a]furo- and thieno pyridines
EP0365089A3 (en) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
DE3936828A1 (de) 1988-11-06 1990-05-10 Boehringer Ingelheim Kg Neue hetrazepine
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5175183A (en) 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
DE4006471A1 (de) 1989-03-03 1990-09-06 Boehringer Ingelheim Kg Neue thienodiazepine
FR2644456B1 (fr) 1989-03-17 1991-07-05 Rhone Poulenc Sante Nouveaux derives du 1h, 3h-pyrrolo(1,2-c)thiazolecarboxamide-7, leur preparation et les compositions pharmaceutiques qui les contiennent
GB8907401D0 (en) 1989-04-01 1989-05-17 Pfizer Ltd Therapeutic agents
US5001123A (en) * 1989-06-08 1991-03-19 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5011847A (en) * 1989-06-08 1991-04-30 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
IE903206A1 (en) 1989-09-07 1991-03-13 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds
US5037853A (en) 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) 1990-04-27 1990-06-20 British Bio Technology Compounds
US5244896A (en) 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
JP3007138B2 (ja) * 1990-11-27 2000-02-07 ファイザー製薬株式会社 新規なヒドロキサム酸とｎ―ヒドロキシ尿素誘導体およびそれらの組成物
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
DK0574510T3 (da) 1991-03-04 2001-12-03 Univ Virginia 2,4-Diaryl-1,3-dithiolaner som platelet activating faktor receptorblokkere og 5-lipoxygenasehæmmere
US5420164A (en) 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
RU2059603C1 (ru) 1991-05-09 1996-05-10 Хоффманн-Ля Рош АГ ПРОИЗВОДНЫЕ α -ЗАМЕЩЕННЫХ АРИЛУКСУСНЫХ КИСЛОТ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US5147893A (en) 1991-05-09 1992-09-15 G. D. Searle & Co. Cyclic phenolic thioethers
GB9114337D0 (en) 1991-07-03 1991-08-21 British Bio Technology Compounds
US5183818A (en) 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5169854A (en) 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5639782A (en) 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5187192A (en) 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5358938A (en) 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
JPH08502243A (ja) 1992-07-13 1996-03-12 サイトメッド，インコーポレイテッド 炎症性および免疫性疾患の治療のための２，５‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
WO1994004537A2 (en) 1992-08-20 1994-03-03 Cytomed, Inc. Dual functional anti-inflammatory and immunosuppressive agents
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
ES2062943B1 (es) 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
BR9508196A (pt) 1994-06-27 1997-09-02 Cytomed Inc Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro

Also Published As

Publication number Publication date
JPH08502243A (ja) 1996-03-12
DE69329550T2 (de) 2001-05-31
EP0650485A1 (en) 1995-05-03
GR3035063T3 (en) 2001-03-30
US6294574B1 (en) 2001-09-25
HUT72601A (en) 1996-05-28
AU4772293A (en) 1994-01-31
US20020177723A1 (en) 2002-11-28
EP0650485B1 (en) 2000-10-11
PT650485E (pt) 2001-03-30
HU9500099D0 (en) 1995-03-28
WO1994001430A1 (en) 1994-01-20
CA2140034A1 (en) 1994-01-20
ES2152952T3 (es) 2001-02-16
AU666578B2 (en) 1996-02-15
DE69329550D1 (de) 2000-11-16
ATE196903T1 (de) 2000-10-15

Similar Documents

Publication Publication Date Title
EE9600184A (et) Kardiovaskulaar-, inflammatoor- ja immuunhaiguste raviühendid ja -meetodid
DK0650485T3 (da) 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
ATE529109T1 (de) Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
MY134841A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
TR199800849T2 (xx) Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
ATE255413T1 (de) Pde iv-inhibitoren zur behandlung der multiplen sklerose
YU81991A (sh) Sinergističke terapeutske kompozicije i postupci
GEP19991706B (en) (54) Heteroarylpiperidines, Pyrrolidines and Piperazines and Their Use As Antipsychotics and Analgetics
DE69529690D1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
BG101130A (bg) Инхибитори на интерлевкин 1 бета-конвертиращ ензим
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
ATE283048T1 (de) Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
RU92016534A (ru) Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта
EP0954334A4 (en) Use of macrophage migration inhibitory factor antagonists for cancer therapy
TW200510311A (en) CCr8 inhibitors
ATE273279T1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
SI1456380T1 (sl) Smad inhibitorji za zdravljenje cns bolezni
DE69431035D1 (de) 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists